160 related articles for article (PubMed ID: 8258192)
1. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.
Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1993; 32(6):445-9. PubMed ID: 8258192
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
[TBL] [Abstract][Full Text] [Related]
3. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
4. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
Zhang J; Herman EH; Ferrans VJ
Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559
[TBL] [Abstract][Full Text] [Related]
5. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
[TBL] [Abstract][Full Text] [Related]
6. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
Herman EH; Ferrans VJ
Cancer Res; 1981 Sep; 41(9 Pt 1):3436-40. PubMed ID: 6790165
[TBL] [Abstract][Full Text] [Related]
7. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
Herman EH; Ferrans VJ; Bhat HB; Witiak DT
Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
9. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.
Herman EH; Ferrans VJ
Lab Invest; 1983 Jul; 49(1):69-77. PubMed ID: 6408310
[TBL] [Abstract][Full Text] [Related]
10. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW
Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981
[TBL] [Abstract][Full Text] [Related]
11. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Herman EH; Zhang J; Ferrans VJ
Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
[TBL] [Abstract][Full Text] [Related]
14. Effects of Doxorubicin (Adriamycin) and [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)]propane (ICRF-187) on skeletal muscle protease activities.
Zima T; Tesar V; Richardson PJ; Mantle D; Preedy VR
Toxicol Appl Pharmacol; 2001 Mar; 171(3):135-40. PubMed ID: 11243912
[TBL] [Abstract][Full Text] [Related]
15. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
Zhang J; Clark JR; Herman EH; Ferrans VJ
J Mol Cell Cardiol; 1996 Sep; 28(9):1931-43. PubMed ID: 8899552
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits.
Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1986; 16(2):102-6. PubMed ID: 3081268
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors.
van Acker SA; Kramer K; Voest EE; Grimbergen JA; Zhang J; van der Vijgh WJ; Bast A
Cancer Chemother Pharmacol; 1996; 38(1):95-101. PubMed ID: 8603459
[TBL] [Abstract][Full Text] [Related]
19. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig.
Perkins WE; Schroeder RL; Carrano RA; Imondi AR
Br J Cancer; 1982 Oct; 46(4):662-7. PubMed ID: 6814473
[TBL] [Abstract][Full Text] [Related]
20. Effects of ICRF 159 on adriamycin-induced cardiomyopathy in rats.
Decorti G; Bartoli Klugmann F; Mallardi F; Klugmann S; Benussi B; Grill V; Baldini L
Cancer Lett; 1983 May; 19(1):77-83. PubMed ID: 6406045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]